Pro Medicus Limited (ASX:PME)
Australia · Delayed Price · Currency is AUD | Market Cap | 13.30B -53.1% |
| Revenue (ttm) | 240.57M +30.3% |
| Net Income | 234.70M +138.8% |
| EPS | 2.24 +138.7% |
| Shares Out | 104.47M |
| PE Ratio | 56.77 |
| Forward PE | 77.45 |
| Dividend | 0.64 (0.50%) |
| Ex-Dividend Date | Feb 26, 2026 |
| Volume | 196,653 |
| Open | 127.10 |
| Previous Close | 127.32 |
| Day's Range | 126.50 - 132.00 |
| 52-Week Range | 107.75 - 336.00 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 182.17 (+39.49%) |
| Earnings Date | May 27, 2026 |
About Pro Medicus
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and commu... [Read more]
Financial Performance
In fiscal year 2025, Pro Medicus's revenue was 212.98 million, an increase of 31.88% compared to the previous year's 161.50 million. Earnings were 115.22 million, an increase of 39.16%.
Financial StatementsNews
Pro Medicus upgraded to Buy from Hold at Jefferies
Jefferies analyst Wei Sim upgraded Pro Medicus (PMCUF) to Buy from Hold with a A$155 price target With over 90% recurring revenue and a capital-light model, the firm remains confident…
Pro Medicus Earnings Call Transcript: H1 2026
Revenue and EBIT grew over 28% year-over-year, driven by record contract wins and expanding cloud-native, full-stack solutions. Major deals in cardiology and pathology, a robust pipeline, and strong margin performance set the stage for accelerated growth in the second half and beyond.
Pro Medicus Quarterly report: H1 2026
Pro Medicus has published its H1 2026 quarterly earnings report on February 11, 2026.
Pro Medicus Slides: H1 2026
Pro Medicus has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 11, 2026.
Pro Medicus Transcript: AGM 2025
Record financial results and strong contract wins drove growth, with expanded dividends and a robust pipeline. Strategic investments, new product offerings, and ambitious targets for the next three years were highlighted, while all AGM resolutions passed with strong shareholder support.
Pro Medicus Slides: FY 2025
Pro Medicus has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 23, 2025.
Pro Medicus Earnings Call Transcript: H2 2025
Record FY25 with revenue up 32%, profit after tax up 40%, and margins at 74%. Secured $520M in new contracts, expanded into cardiology and digital pathology, and maintained 100% renewal rate. Cloud and AI offerings drive competitive advantage.
Pro Medicus Annual report: H2 2025
Pro Medicus has published its H2 2025 annual report on August 13, 2025.
Pro Medicus Slides: H2 2025
Pro Medicus has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 13, 2025.
Pro Medicus Earnings Call Transcript: H1 2025
Record first-half results with 31% revenue and 43% profit growth, driven by major new contracts, renewals, and expanding U.S. market share. Margins remain strong, pipeline replenishment is robust, and cloud-based innovation and AI position the business for continued growth.
Pro Medicus Quarterly report: H1 2025
Pro Medicus has published its H1 2025 quarterly earnings report on February 12, 2025.
Pro Medicus Slides: H1 2025
Pro Medicus has posted slides in relation to its H1 2025 quarterly earnings report, which was published on February 12, 2025.
Pro Medicus initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Pro Medicus (PMCUF) with an Overweight rating and A$300 price target PME Visage 7 software “creates significant value for its customers, underpinning our confidenc...
Pro Medicus Shares Gain on Upbeat Outlook
Shares of the ASX-listed Pro Medicus Limited ($AU:PME) extended their rally today, driven by the company’s upbeat outlook for FY25. In its AGM (annual general meeting) presentation for FY24, the…
Pro Medicus Transcript: AGM 2024
Record financial results, major contract wins, and increased dividends highlighted a strong year. Strategic focus remains on the U.S. market, AI, and cloud innovation, with robust governance and high shareholder support for all resolutions.
Pro Medicus Slides: FY 2024
Pro Medicus has posted slides in relation to its FY 2024 quarterly earnings report, which was published on November 24, 2024.
Pro Medicus Earnings Call Transcript: H2 2024
Revenue and profit after tax rose 29.3% and 36.5% year-over-year, driven by record new sales, cloud-based contract wins, and strong North American growth. Margins improved, pipeline remains robust, and the company is expanding into AI and cardiology, with no contract losses reported.
Pro Medicus Annual report: H2 2024
Pro Medicus has published its H2 2024 annual report on August 13, 2024.
Pro Medicus Slides: H2 2024
Pro Medicus has posted slides in relation to its H2 2024 quarterly earnings report, which was published on August 13, 2024.
Pro Medicus Earnings Call Transcript: H1 2024
Pro Medicus Quarterly report: H1 2024
Pro Medicus has published its H1 2024 quarterly earnings report on February 14, 2024.
Pro Medicus Slides: H1 2024
Pro Medicus has posted slides in relation to its H1 2024 quarterly earnings report, which was published on February 14, 2024.
Pro Medicus Transcript: AGM 2023
Pro Medicus Slides: FY 2023
Pro Medicus has posted slides in relation to its FY 2023 quarterly earnings report, which was published on November 19, 2023.